Peptides for muscle gain: the evidence

Most of the peptides marketed for muscle gain have never been tested for muscle gain in a controlled human trial. That is the honest starting point. The two names that come up most often, ipamorelin and CJC-1295, have a little human pharmacology behind them and no published efficacy trial for building muscle in healthy adults. A 2026 narrative review in Frontiers in Endocrinology sorted the whole field into evidence tiers and found that the strongest human data sits several rungs below what the online protocols imply^[1].

How to weight the evidence

Not all evidence carries the same weight, and the muscle-gain peptide conversation tends to flatten the difference. A useful hierarchy runs from randomised controlled trials that measure the outcome you care about, down through early-phase human studies that measure a hormone rather than an outcome, then animal experiments, and finally forum reports. The Frontiers review applied that kind of stratification directly, contrasting peer-reviewed pharmacokinetic and clinical evidence against the self-administration protocols that circulate in unregulated supply chains^[1]. Its tiers run from regulatory-grade trial data at the top down to a complete absence of human studies at the bottom, and most performance peptides sit near that bottom.

What has genuine human data, and what it measured

CJC-1295 has the strongest human dataset of any peptide in this group, and it is worth being precise about what that dataset shows. A 2006 placebo-controlled study by Teichman and colleagues gave healthy adults single and repeated injections and reported dose-dependent rises in growth hormone of two- to tenfold for six days or more, IGF-1 up 1.5- to threefold for nine to eleven days, and a half-life of 5.8 to 8.1 days^[2]. A companion study by Ionescu and Frohman found that the pituitary kept its natural pulsatile growth-hormone rhythm during that sustained stimulation^[3].

Both are real findings. Neither measured muscle mass, strength, or body composition. They measured hormone levels in the blood, which is a step removed from the outcome anyone taking these compounds actually wants. The trials also characterised the response at doses reported in the range of 30 to 90 micrograms per kilogram^[2][3], but they were designed to describe pharmacology, not to establish a therapeutic dose.

Ipamorelin sits one rung lower. Its published human work is short pharmacokinetic characterisation confirming a modest, short-lived growth-hormone pulse, with no controlled efficacy trial for any indication^[1]. So the claim that ipamorelin builds muscle has, at present, no direct human trial behind it at all.

What rests on animal data

The most concrete muscle-specific finding for this pair comes from mice, not people. A 2026 primer in the American Journal of Sports Medicine noted that CJC-1295 combined with ipamorelin improved maximum tetanic tension, a measure of muscle force, in murine models of glucocorticoid-induced muscle loss, while stating plainly that the finding is limited to animal studies^[4]. The same review concluded that 'information regarding the indications, dosing, frequency, and duration of treatment remains unknown'^[4]. Animal data can justify running a human trial. It cannot stand in for one.

What rests on anecdote

Below the animal data is the largest category by volume and the weakest by quality: self-reports. Forum posts and clinic testimonials describe better recovery, sleep, and body composition on growth-hormone-axis peptides. These accounts are uncontrolled and unblinded, and they are mixed in with training and diet changes, so they cannot separate the peptide from everything else the person changed. The Frontiers review flagged a second problem specific to this supply chain: the product itself is uncertain, because a vial labelled CJC-1295 may contain the short-acting version, a different peptide, or a degraded one, with no quality control unless the buyer pays for independent testing^[1].

What we don't yet know

The list of open questions is long. There is no randomised trial testing whether either peptide increases lean mass in healthy adults, no defensible human dose-response for a muscle outcome, and no long-term safety data covering months or years of use^[1]. The theoretical concerns that travel with sustained growth-hormone and IGF-1 elevation, including glucose dysregulation and the IGF-1-linked cancer questions that apply across this drug class, have not been resolved for these compounds.

There is also the anti-doping dimension. Both ipamorelin and CJC-1295 are named on the WADA Prohibited List under section S2, banned in and out of competition, which is a hard stop for any competing athlete regardless of local medicines law. The jurisdiction detail sits on the ipamorelin regulation pages and the CJC-1295 regulation pages.

Where this leaves the evidence

The biology of the growth-hormone axis is real, and the human pharmacology of CJC-1295 is better characterised than most grey-market peptides. What is missing is the part that matters for muscle gain: a controlled human trial that measures muscle, not a hormone. Until that trial exists, claims about these peptides building muscle are extrapolations from hormone-level and animal data, and they should be read as such.

This article is for educational purposes only. It does not constitute medical advice, and it is not a dosing guide. If you are considering any growth-hormone-axis peptide, talk it through with a qualified healthcare provider who knows your history before making any decision.